ATE175190T1 - Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten - Google Patents

Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten

Info

Publication number
ATE175190T1
ATE175190T1 AT92921435T AT92921435T ATE175190T1 AT E175190 T1 ATE175190 T1 AT E175190T1 AT 92921435 T AT92921435 T AT 92921435T AT 92921435 T AT92921435 T AT 92921435T AT E175190 T1 ATE175190 T1 AT E175190T1
Authority
AT
Austria
Prior art keywords
dimethylethyl
oxo
cyano
hexanoates
preparing
Prior art date
Application number
AT92921435T
Other languages
English (en)
Inventor
Donald Eugene Butler
Tung Van Le
Alan Millar
Thomas Norman Nanninga
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE175190T1 publication Critical patent/ATE175190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C07C255/21—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT92921435T 1991-10-11 1992-10-05 Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten ATE175190T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/775,162 US5155251A (en) 1991-10-11 1991-10-11 Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate

Publications (1)

Publication Number Publication Date
ATE175190T1 true ATE175190T1 (de) 1999-01-15

Family

ID=25103514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92921435T ATE175190T1 (de) 1991-10-11 1992-10-05 Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten

Country Status (16)

Country Link
US (1) US5155251A (de)
EP (1) EP0643689B1 (de)
JP (2) JP3241723B2 (de)
AT (1) ATE175190T1 (de)
AU (1) AU667320B2 (de)
CA (1) CA2116973C (de)
DE (1) DE69228073T2 (de)
DK (1) DK0643689T3 (de)
ES (1) ES2129457T3 (de)
FI (1) FI941632A0 (de)
MX (1) MX9205824A (de)
NO (1) NO300208B1 (de)
PT (1) PT100943B (de)
SG (1) SG46599A1 (de)
WO (1) WO1993007115A1 (de)
ZA (1) ZA927793B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
JP3171931B2 (ja) * 1992-06-02 2001-06-04 高砂香料工業株式会社 （Ｒ）−（−）−４−シアノ−３−ヒドロキシ酪酸ｔ−ブチルエステル及びその製造方法
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
GB9512837D0 (en) * 1995-06-23 1995-08-23 Zeneca Ltd reduction of ketone groups
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5908953A (en) * 1996-12-18 1999-06-01 Mitsubishi Chemical Corporation Method for producing (R)-4-cyano-3-hydroxybutyric acid lower alkyl ester
JPH11171850A (ja) * 1997-12-12 1999-06-29 Kanegafuchi Chem Ind Co Ltd 酪酸エステル誘導体の製造方法
EP1054860B1 (de) * 1997-12-19 2007-04-25 Pfizer Ireland Pharmaceuticals Verfahren zur herstellung von 1,3-diolen
EP1077212B1 (de) * 1998-04-30 2003-08-20 Kaneka Corporation Verfahren zur herstellung von derivaten der 6-cyanomethyl-1,3-dioxan-4-essigsäure
PT1619191E (pt) 1998-08-05 2010-12-21 Kaneka Corp Processo de produção de derivados opticamente activos do ácido 2-[6-(hidroximetil)-1,3-dioxan-4-il]acético
KR100313668B1 (ko) * 1999-02-03 2001-11-26 박영구 (ｒ)-4-시아노-3-히드록시부티르산 에스테르의 제조방법
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
DE60009836T2 (de) * 1999-06-04 2005-04-21 Kaneka Corp Verfahren zur herstellung von 5-hydroxy-3-oxo-pentansäure-derivaten
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
ES2258030T3 (es) 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
EP1584616A1 (de) 1999-12-17 2005-10-12 Pfizer Science and Technology Ireland Limited Verfahren auf industrieller Basis zur Herstellung von Astorvastatin-Trihydrat Hemi-Kalziumsalz in kristalliner Form
CN100368386C (zh) * 2000-05-31 2008-02-13 中国医学科学院药物研究所 （±）对氟-2-（2-甲基-丙酰基）-4-氧-n，3-二苯基-苯丁酰胺的合成方法以及其中的中间体
CN101250133B (zh) * 2000-05-31 2010-06-09 中国医学科学院药物研究所 (±)对氟-2-(2-甲基-丙酰基)-4-氧-n，3-二苯基-苯丁酰胺的合成方法以及其中的中间体
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (de) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carbonsäuresalze von beta-Alaninestern oder -Amiden
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
BR0210666A (pt) 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
EP1404642B1 (de) 2001-07-06 2010-02-17 Basf Se Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
MXPA03012045A (es) 2001-07-06 2004-03-29 Teva Pharma Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
HUP0401145A3 (en) 2001-07-06 2008-08-28 Ciba Sc Holding Ag Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
AU2002255479B2 (en) 2001-07-30 2008-09-11 Dr. Reddy's Laboratories Ltd. Crystalline forms VI and VII of atorvastatin clacium
JP4765217B2 (ja) * 2001-07-30 2011-09-07 住友化学株式会社 （ｒ）−４−シアノ−３−ヒドロキシブタン酸エステルの製造法
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
KR100849880B1 (ko) * 2001-12-20 2008-08-01 주식회사 중외제약 광학활성 2-[6-(치환된 알킬)-1,3-디옥산-4-일]아세트산유도체의 신규 제조 방법
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
CN100357289C (zh) * 2002-08-06 2007-12-26 沃尼尔·朗伯有限责任公司 制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
WO2004015132A2 (en) * 2002-08-09 2004-02-19 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
WO2004022053A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
EP1615883A1 (de) * 2003-04-14 2006-01-18 Warner-Lambert Company Verfahren zur herstellung von 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäurephenylamid
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2004103960A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
AU2003272080A1 (en) * 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
EP1711489B1 (de) * 2003-12-29 2012-12-26 LEK Pharmaceuticals d.d. Verfahren zur herstellung von amorpher (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxan-4-yl-essigsäure
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
US7645888B2 (en) * 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
CA2621507A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
ATE432276T1 (de) * 2005-09-09 2009-06-15 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
WO2008042876A2 (en) 2006-10-02 2008-04-10 Codexis, Inc. Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
WO2008059366A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Process for the preparation of cis-1, 3-diols from the corresponding beta-hydroxy ketones employing microbial ketone reductases
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009013633A2 (en) * 2007-07-20 2009-01-29 Actavis Group Ptc Ehf Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
EP2532660B1 (de) * 2007-08-03 2014-09-10 Pfizer Products Inc. Verfahren zur Herstellung chiraler Verbindungen
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB2474687A (en) 2009-10-23 2011-04-27 Phoenix Chemicals Ltd A continuous process for the production of (R)-6-cyano-5-hydroxy-3-oxo-hexanoic acid tert-butyl ester (and derivatives)
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
EP2614057B1 (de) 2010-09-09 2015-10-21 DSM Sinochem Pharmaceuticals Netherlands B.V. Salze aus 7-amino-3,5-dihydroxyheptanonsäureestern
US20140335179A1 (en) 2011-07-01 2014-11-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
CN102766072B (zh) * 2012-08-07 2013-12-25 浙江宏元药业有限公司 一种制备阿托伐他汀钙手性侧链的方法
CN103145584B (zh) * 2013-03-05 2015-08-26 复旦大学 一种合成(3r,5r)-3,5-二羟基-6-氰基己酸酯的方法
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN108033899B (zh) * 2017-12-06 2020-04-10 浙江科技学院 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
AU2764192A (en) 1993-05-03
JP2002030060A (ja) 2002-01-29
ZA927793B (en) 1994-04-11
SG46599A1 (en) 1998-02-20
FI941632A7 (fi) 1994-04-08
NO300208B1 (no) 1997-04-28
ES2129457T3 (es) 1999-06-16
NO941280D0 (no) 1994-04-08
JPH07500105A (ja) 1995-01-05
NO941280L (no) 1994-04-08
EP0643689B1 (de) 1998-12-30
DE69228073D1 (de) 1999-02-11
PT100943A (pt) 1993-10-29
CA2116973C (en) 2004-09-21
WO1993007115A1 (en) 1993-04-15
FI941632L (fi) 1994-04-08
FI941632A0 (fi) 1994-04-08
JP3241723B2 (ja) 2001-12-25
DE69228073T2 (de) 1999-06-10
EP0643689A1 (de) 1995-03-22
DK0643689T3 (da) 1999-08-30
MX9205824A (es) 1993-04-01
PT100943B (pt) 1999-07-30
CA2116973A1 (en) 1993-04-15
JP3429500B2 (ja) 2003-07-22
US5155251A (en) 1992-10-13
AU667320B2 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
ATE175190T1 (de) Prozess zur darstellung von (5r)-1,1- dimethylethyl-6-cyano-5-oxo-hexanoaten
DE69014396D1 (de) Verfahren zur Herstellung von permeationsbeständigen Silikonelastomer enthaltenden Mehrschichtstrukturen sowie dadurch hergestellte Artikel.
DE3885366D1 (de) Verfahren zur Herstellung von Pyrrolo-(3,4-c)pyrrolen.
DE3883408D1 (de) Verfahren zur Herstellung von Avermectinen und die verwendeten Kulturen.
DE69014707D1 (de) Verfahren zur Herstellung von CMOS-Feldeffekt-Transistoren.
DE68915220D1 (de) Vorrichtung zur Herstellung von Schichtstoffen.
DE68918778D1 (de) Verfahren zur Herstellung von ungesättigte Lactone enthaltenden Gemischen, hierdurch hergestellte Verbindungen und organoleptische Verwendung dieser Verbindungen.
FI940046A0 (fi) Menetelmä ruokatuotteen valmistamiseksi
DE68921655D1 (de) Verfahren zur Herstellung von Mustern.
DE69009614D1 (de) Verfahren zur Herstellung von (S)-gamma-Hydroxymethyl-alpha,beta-Butenolid.
EP0014958A3 (de) Verfahren zur Herstellung von 4,5-Perfluor-1,3-dioxolanen
AT371729B (de) Verfahren zur herstellung von laminaten, insbesondere skis und vakuumformvorrichtung
DE68922360D1 (de) Verfahren zur Herstellung von Metall-Polyimid-Verbundwerkstoffen.
EP0268996A3 (en) Lactonic degradation product, process for its preparation and its use
DE69013132D1 (de) Verfahren zur Herstellung von Octa-2,7-dien-1-ol.
AU2613892A (en) Process for producing dimethyl ether
SE8003155L (sv) Sett att framstella 2,3-dimetylbuten-2
DE69026585D1 (de) Verfahren zur Herstellung von R-(-)-3-Halogeno-1,2-propandiol durch Behandlung mit Mikroorganismen
ATE80383T1 (de) Verfahren zur herstellung sulfatierter alkanoloder alkylphenol-oxethylate mit erniedrigtem gehalt an 1,4-dioxan.
DE68917379D1 (de) Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE69022014D1 (de) Verfahren zur Herstellung von S-(+)-3-Halogeno-1,2-propandiol durch Behandlung mit Mikroorganismen.
CA2064740A1 (en) Method for Enrichment of Oxygen 18 with a Laser
DE69012471D1 (de) Verfahren zur Herstellung von delta-Lactonen.
KR920021069A (ko) 우뭇가사리(天草)를 이용한 청량 음료의 제조방법
DE59006458D1 (de) Verfahren zur Herstellung von cyclischen Amidinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee